Skip to main content
. 2018 Apr 20;4(2):00120-2017. doi: 10.1183/23120541.00120-2017

TABLE 3.

Drugs and drug regimens used

Patients
Drug regimens (n=25)  
 Docetaxel 24 (21)
 Paclitaxel 9 (8)
 Erlotinib 17 (15)
 Vemurafenib 1 (1)
 Gemcitabine 26 (23)
 Vinorelbine 8 (7)
 Pemetrexed 6 (5)
 Afatinib 3 (3)
 Abemaciclib 1 (1)
 Platin docetaxel 1 (1)
 Platin pemetrexed 4 (3)
 Platin gemcitabine 1 (1)
 Platin paclitaxel 1 (1)
 Platin paclitaxel bevacizumab 1 (1)
 Platin vinorelbine 1 (1)
 Platin etoposide 1 (1)
 Paclitaxel trastuzumab 1 (1)
 Vinorelbin trastuzumab 1 (1)
 Abemaciclib necitumumab 1 (1)
 Pemetrexed bevacizumab 1 (1)
 Paclitaxel bevacizumab 2 (2)
 Pertuzumab afatinib 1 (1)
 Paclitaxel erlotinib 1 (1)
 Cytarabine 1 (1)
 Everolimus 1 (1)
Drugs (n=18)
 Docetaxel 25 (22)
 Paclitaxel 15 (13)
 Erlotinib 18 (16)
 Vemurafenib 1 (1)
 Gemcitabine 27 (23)
 Vinorelbine 10 (9)
 Pemetrexed 11 (10)
 Afatinib 4 (3)
 Abemaciclib 2 (2)
 Trastuzumab 2 (2)
 Necitumumab 1 (1)
 Bevacizumab 4 (3)
 Vemurafenib 1 (1)
 Pertuzumab 1 (1)
 Etoposide 1 (1)
 Platin 10 (9)
 Everolimus 1 (1)
 Cytarabine 1 (1)

Data are presented as n (%), unless otherwise stated.